Search Results

Showing results 1971 - 1980 for weill cornell connect patient portal

Structural organization of a 17 KB segment of the alpha 2 collagen

...Connect Departments Alumni News Events Weill Cornell Medicine....

https://geneticmedicine.weill.cornell.edu/publications/structural-organization-17-kb-segment-alpha-2-collagen-gene-evaluation-r-loop-mapping

Epigenetic Modifying Agents Sensitize EBV+ Lymphomas to Immunotherapy | Enterprise Innovation

...With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/epigenetic-modifying-agents-sensitize-ebv-lymphomas

Inflammasome Agonists for Vaccine and Immunotherapy | Enterprise Innovation

...With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/inflammasome-agonists-vaccine-and-immunotherapy

A Small Molecule Promotes Bone Healing via P38 Activation | Enterprise Innovation

...With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/small-molecule-promotes-bone-healing-p38-activation

MicroRNA Expression Levels are Predictive of Human Allograft Status | Enterprise Innovation

...With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/microrna-expression-levels-are-predictive-human

SLC45A3-ELK4 as a Non-invasive Diagnostic Marker for Prostate Cancer | Enterprise Innovation

...With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/slc45a3-elk4-non-invasive-diagnostic-marker

Improved Contrast-Enhanced MRA with Mask or Arterial Phase Averaging | Enterprise Innovation

...With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/improved-contrast-enhanced-mra-mask-or-arterial

Peptide Nanofibers for Targeted Delivery of Anti-Cancer Therapeutic and Diagnostic Agents | Enterprise Innovation

...With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/peptide-nanofibers-targeted-delivery-anti-cancer

Small Molecules that Protect Against Lipofuscin Toxicity to Prevent Blindness | Enterprise Innovation

...With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/small-molecules-protect-against-lipofuscin-toxicity

Iron Chelators for the Treatment of Adult Neuronal Ceroid Lipofuscinosis | Enterprise Innovation

...With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/iron-chelators-treatment-adult-neuronal-ceroid

Showing results 1971 - 1980 for weill cornell connect patient portal